Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
What is your approach to duration of antibiotic therapy for treatment of a bacterial lung abscess?
Related Questions
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
Do you administer prophylactic antibiotics to prevent VAP following intubation in patients with acute brain injury?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
How would you treat a patient with psoriatic arthritis who developed disseminated histoplasmosis while on adalimumab and previously failed all non-biologic DMARDs?
What further evaluation do you pursue for patients who present with vague symptoms such as subjective fevers or intermittent night sweats, who have no pulmonary symptoms but have a positive IGRA?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
